Metformin in Diabetic Patients with Heart Failure: Safe and Effective
- 229 Downloads
Management of diabetic patients with heart failure is a complex endeavor. The initial reluctance to use metformin in these patients has given way to a broader acceptance after clinical trials and meta-analyses have revealed that some of the insulin-sensitizing agents lead to adverse cardiovascular events. We have proposed that an increase of substrate uptake by the insulin-resistant heart is detrimental because the heart is already flooded with fuel. In light of this evidence, metformin offers a unique safety profile in the patient with diabetes and heart failure. Our article expands on the use of metformin in patients with heart failure. We propose that the drug targets both the source as well as the destination (in this case the heart) of excess fuel. We consider treatment of diabetic heart failure patients with metformin both safe and effective.
KeywordsType 2 diabetes mellitus Heart failure Anti-diabetic drugs
We thank Roxy A. Tate for expert editorial assistance. Work in H.T.’s lab is supported by the NHLBI (R01-HL061483 and R01-HL073162.)
Compliance with Ethics Guidelines
Conflict of Interest
Heinrich Taegtmeyer, Ijeoma Ananaba Ekeruo and Amirreza Solhpour declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any original data with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.•• Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010;16(3):200–6. A retrospective cohort study that included 401 patients with DM and severe heart failure followed between 1994 and 2008. Although there was a trend to improvement of outcomes in the patients on metformin, the results were not statistically significant.PubMedCrossRefGoogle Scholar
- 16.Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res. 1998; 40(2):239–47.Google Scholar
- 19.Young ME, Yan J, Razeghi P, Cooksey RC, Guthrie PH, Stepkowski SM, McClain DA, Tian R, Taegtmeyer H. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio. 2007;1:1251–262.Google Scholar
- 24.•• Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2010;4(1):53–8. A multicenter retrospective cohort study that studied metformin use in ambulatory patients with DM and CHF. Here, metformin use was associated with a significantly lower rate of mortality. Surprisingly, in this study the effect of the use of metformin on the rate of hospitalizations was minimal.PubMedCrossRefGoogle Scholar
- 28.Brunton L, Chabner B, Knollman B. Goodman and Gillman's the pharmacological basis of therapeutics. New York: McGraw Hill Professional Publications; 2010.Google Scholar
- 31.Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.Google Scholar
- 34.• Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-SMAD3 signalling pathway. Cardiovasc Res. 2010;87(3):504–13. A rodent animal study investigating cardioprotective effects of metformin. Specifically the role of metformin in decreasing cardiac fibrosis was investigated and a pathway was proposed.PubMedCrossRefGoogle Scholar
- 43.Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: The loss of protective akt signalling. Cardiovasc Res. 2013;99(4):694–704.Google Scholar
- 44.•• Sen S, Kundu BK, Wu HC, Hashmi SS, Guthrie P, Locke LW, et al. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc. 2013;2(3):e004796. This study shows for the fist time that an intermediary metabolie (glucose 6-phosphate, G6P) regulates mTOR, the endoplasmic reticulum (ER) stress response and contratile efficiency in animal models and the failing human heart. Metformin improves contractile function by reducing G6P levels and ER stress.PubMedCrossRefGoogle Scholar
- 49.Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402.PubMedCrossRefGoogle Scholar
- 50.Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; (4):CD002967.Google Scholar
- 51.• Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the shhf rat model. Diabetes. 2012;61(4):944–53. Longitudinal animal study where rats with hypertensive heart disease were treated with metformin and rosiglitazone. Metformin was associated with improved cardiac outcomes and decreased progression to heart failure.PubMedCrossRefGoogle Scholar
- 55.Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. J Am Coll Cardiol HF. 2013;1(2):93–102.Google Scholar